Nalmefene and alcohol dependence: A new approach or the same old unacceptable marketing?

Figures & data

Table 1 Variations of biomarkers. Pooled subpopulation of the ESENSE 1 and 2 trials with high-risk or very high-risk drinking

Efficacy variables	Placebo Geometric mean	Nalmefene Geometric mean	Significance
GGT
Baseline	57.6	55.8	P<0.0005
Week 24	53.0	43.5
ALAT
Baseline	29.2	29.3	P<0.0001
Week 24	30.7	26.0
ASAT
Baseline	31.1	31.5	P=0.0003
Week 24	31.2	27.2

Note: Adapted from 5.